JP2024507788A5 - - Google Patents
Info
- Publication number
- JP2024507788A5 JP2024507788A5 JP2023548941A JP2023548941A JP2024507788A5 JP 2024507788 A5 JP2024507788 A5 JP 2024507788A5 JP 2023548941 A JP2023548941 A JP 2023548941A JP 2023548941 A JP2023548941 A JP 2023548941A JP 2024507788 A5 JP2024507788 A5 JP 2024507788A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- compound according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163149927P | 2021-02-16 | 2021-02-16 | |
| US63/149,927 | 2021-02-16 | ||
| PCT/US2022/016261 WO2022177840A1 (en) | 2021-02-16 | 2022-02-14 | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507788A JP2024507788A (ja) | 2024-02-21 |
| JP2024507788A5 true JP2024507788A5 (https=) | 2025-02-13 |
Family
ID=80625127
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023548941A Pending JP2024507788A (ja) | 2021-02-16 | 2022-02-14 | Ｈｉｖインテグラーゼ阻害剤として有用な四環式複素環化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11958864B2 (https=) |
| EP (1) | EP4294813B1 (https=) |
| JP (1) | JP2024507788A (https=) |
| KR (1) | KR20230147131A (https=) |
| CN (1) | CN117083282A (https=) |
| AR (1) | AR124868A1 (https=) |
| CA (1) | CA3208396A1 (https=) |
| ES (1) | ES3048138T3 (https=) |
| MX (1) | MX2023009445A (https=) |
| TW (1) | TW202246286A (https=) |
| WO (1) | WO2022177840A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY201239A (en) | 2019-03-22 | 2024-02-13 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| PE20221569A1 (es) | 2020-02-24 | 2022-10-06 | Gilead Sciences Inc | Compuestos tetraciclicos para el tratamiento de infecciones por vih |
| ES3064867T3 (en) | 2020-09-30 | 2026-04-29 | Gilead Sciences Inc | Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv |
| US11613546B2 (en) | 2021-01-19 | 2023-03-28 | Gilead Sciences, Inc. | Substituted pyridotriazine compounds and uses thereof |
| TW202446773A (zh) | 2022-04-06 | 2024-12-01 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| EP4704976A1 (en) * | 2023-04-28 | 2026-03-11 | Merck Sharp & Dohme LLC | Delivery devices for anti-hiv compounds |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010011814A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| JP5551697B2 (ja) * | 2008-07-25 | 2014-07-16 | ビーブ・ヘルスケア・カンパニー | 化合物 |
| ES2448766T3 (es) * | 2008-07-25 | 2014-03-17 | Viiv Healthcare Company | Profármacos de dolutegravir |
| DK2620436T3 (en) * | 2010-09-24 | 2018-07-30 | Shionogi & Co | Substituted polycyclic carbamoylpyridone derivative prodrug |
| WO2017113288A1 (en) * | 2015-12-31 | 2017-07-06 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as hiv integrase inhibitors |
| JOP20190130A1 (ar) * | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| EP3573984A4 (en) * | 2017-01-26 | 2020-07-29 | Merck Sharp & Dohme Corp. | USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS |
-
2022
- 2022-02-14 MX MX2023009445A patent/MX2023009445A/es unknown
- 2022-02-14 ES ES22707560T patent/ES3048138T3/es active Active
- 2022-02-14 US US17/670,689 patent/US11958864B2/en active Active
- 2022-02-14 EP EP22707560.3A patent/EP4294813B1/en active Active
- 2022-02-14 CN CN202280022034.3A patent/CN117083282A/zh active Pending
- 2022-02-14 TW TW111105302A patent/TW202246286A/zh unknown
- 2022-02-14 WO PCT/US2022/016261 patent/WO2022177840A1/en not_active Ceased
- 2022-02-14 CA CA3208396A patent/CA3208396A1/en active Pending
- 2022-02-14 JP JP2023548941A patent/JP2024507788A/ja active Pending
- 2022-02-14 KR KR1020237031339A patent/KR20230147131A/ko active Pending
- 2022-02-14 AR ARP220100289A patent/AR124868A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024507788A5 (https=) | ||
| JP5562255B2 (ja) | ウイルス感染を治療する方法 | |
| JP2004509061A5 (https=) | ||
| CN101743004A (zh) | 治疗用组合物及其用途 | |
| HK1255463A1 (zh) | Hbv衣壳组装抑制剂和干扰素的组合疗法 | |
| EP3356355B1 (en) | Compounds and combinations for the treatment of hiv | |
| CN1758905A (zh) | 青蒿素在治疗致癌病毒诱导的肿瘤和治疗病毒感染中的应用 | |
| CN111867582A (zh) | 衣壳组装调节剂给药方案 | |
| JP4627356B2 (ja) | ウイルス性心筋炎の予防または治療薬剤 | |
| JP2009525265A5 (https=) | ||
| JP2000517323A (ja) | Ｂ型肝炎およびレトロウイルス関連疾患の治療のためのジカフェオイルキナ酸の新規使用および新規カフェオイルキナ酸誘導体 | |
| NZ541187A (en) | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) with an inhibitor of cytochrome P450, such as protease inhibitors | |
| US5179096A (en) | Therapeutic application of flouroquinolone derivatives | |
| JP2008521934A5 (https=) | ||
| JP2002528508A (ja) | Ｂ型肝炎治療のための組合せ療法 | |
| WO2015120057A1 (en) | Pharmaceutical combinations against co-infection with hiv and tuberculosis | |
| AU2018239257B2 (en) | HIV post-exposure prophylaxis | |
| US6441009B1 (en) | Agent and method of preventing and treating heavy metal exposure and toxicity | |
| CN114051411B (zh) | Eyp001与ifn用于治疗hbv感染的协同效应 | |
| US5432187A (en) | Benzimidazole anthelmintic in the treatment of microsporidial infections | |
| CN104780921A (zh) | Hcv的大环蛋白酶抑制剂、非核苷hcv抑制剂和利托那韦的组合 | |
| CN111065379A (zh) | 用于治疗病毒感染的组合药物制剂 | |
| JP2007516296A5 (https=) | ||
| RU2023123879A (ru) | Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич | |
| JPH07503252A (ja) | 置換アザスペラン化合物投与によるｈｉｖ誘発エイズ遅延方法 |